Lara A Dunn Selected Research

Fatigue

11/2017

Phase 2 study evaluating the combination of sorafenib and temsirolimus in the treatment of radioactive iodine-refractory thyroid cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Lara A Dunn Research Topics

Disease

12	Neoplasms (Cancer) 01/2024 - 01/2018
7	Squamous Cell Carcinoma of Head and Neck 01/2023 - 11/2016
4	Squamous Cell Carcinoma (Epidermoid Carcinoma) 12/2023 - 01/2018
3	Head and Neck Neoplasms (Head and Neck Cancer) 01/2023 - 01/2020
3	Thyroid Neoplasms (Thyroid Cancer) 01/2019 - 11/2017
2	Carcinoma (Carcinomatosis) 01/2024 - 11/2017
2	Neoplasm Metastasis (Metastasis) 01/2021 - 11/2017
2	Necrosis 01/2020 - 01/2020
2	Stomatitis 01/2020 - 11/2017
1	Basal Cell Carcinoma (Rodent Ulcer) 04/2024
1	Neuroendocrine Carcinoma 12/2023
1	Olfactory Esthesioneuroblastoma (Esthesioneuroblastoma) 12/2023
1	Sinonasal undifferentiated carcinoma 12/2023
1	Adenoid Cystic Carcinoma (Cylindroma) 12/2023
1	Salivary Gland Neoplasms (Salivary Gland Cancer) 12/2023
1	Neutropenia 01/2021
1	Deglutition Disorders (Dysphagia) 01/2021
1	Inflammation (Inflammations) 01/2021
1	Nasopharyngeal Carcinoma 01/2021
1	Oropharyngeal Neoplasms 01/2021
1	Respiratory Insufficiency (Respiratory Failure) 01/2021
1	Rupture 01/2021
1	Merkel Cell Carcinoma 01/2020
1	Facial Pain (Myofacial Pain) 01/2020
1	Osteoradionecrosis 01/2020
1	Body Weight (Weight, Body) 01/2018
1	Squamous Cell Neoplasms (Squamous Cell Cancer) 01/2018
1	Hyperglycemia 11/2017
1	Fatigue 11/2017
1	Anemia 11/2017

Drug/Important Bio-Agent (IBA)

2	NivolumabIBA 12/2023 - 01/2020
2	Immune Checkpoint InhibitorsIBA 04/2022 - 01/2018
2	Immunoglobulins (Immunoglobulin)IBA 01/2020 - 01/2019
2	cemiplimabIBA 01/2020 - 01/2018
2	Proteins (Proteins, Gene)FDA Link 01/2019 - 01/2018
2	IodineIBA 01/2019 - 11/2017
1	HhAntag691IBA 04/2024
1	Cytotoxins (Cytolysins)IBA 12/2023
1	IpilimumabIBA 12/2023
1	RNA (Ribonucleic Acid)IBA 12/2023
1	T-Cell Antigen Receptors (T-Cell Receptor)IBA 12/2023
1	avelumabIBA 01/2021
1	Cisplatin (Platino)FDA LinkGeneric 01/2021
1	Monoclonal AntibodiesIBA 01/2020
1	PlatinumIBA 01/2020
1	AlpelisibIBA 01/2020
1	Radiation-Sensitizing AgentsIBA 01/2020
1	Cetuximab (Erbitux)FDA Link 01/2020
1	VemurafenibIBA 01/2019
1	Tyrosine Kinase InhibitorsIBA 01/2019
1	Thyroglobulin FDA Link 01/2019
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2019
1	afliberceptIBA 01/2019
1	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 01/2019
1	AfatinibIBA 01/2018
1	Ribavirin (Virazole)FDA LinkGeneric 01/2018
1	Oncogene Proteins (Oncogene Protein)IBA 01/2018
1	Carboplatin (JM8)FDA LinkGeneric 01/2018
1	Paclitaxel (Taxol)FDA LinkGeneric 01/2018
1	Phosphotransferases (Kinase)IBA 11/2017
1	Sorafenib (BAY 43-9006)FDA Link 11/2017
1	temsirolimus FDA Link 11/2017

Therapy/Procedure

6	Radiotherapy 04/2024 - 11/2017
4	Drug Therapy (Chemotherapy) 01/2024 - 11/2017
4	Proton Therapy 01/2023 - 01/2020
3	Chemoradiotherapy 01/2024 - 11/2017
3	Therapeutics 04/2022 - 11/2017
2	Induction Chemotherapy 12/2023 - 01/2018
2	Re-Irradiation 01/2023 - 01/2020
2	Immunotherapy 04/2022 - 11/2016
1	Neoadjuvant Therapy 04/2022
1	Drug Tapering 01/2020
1	Retreatment 01/2020
1	Intensity-Modulated Radiotherapy (Radiotherapy, Intensity Modulated) 11/2017